Long Term Effects of Epoetin Alfa in Patients with ST- Elevation Myocardial Infarction

Autor: Arnoud W J van 't Hof, Wiek H. van Gilst, José P.S. Henriques, Hans O. Peels, J. Wouter Jukema, Dirk J. van Veldhuisen, Sandra K. Achterhof, Peter van der Meer, Lennaert Kleijn, Adriaan A. Voors, Jurriën M. ten Berg, Hans L. Hillege, Marieke L. Fokkema, Jeroen Vos, Anne M. S. Belonje
Přispěvatelé: Science and Society, Athena Institute, Life Course Epidemiology (LCE), Cardiovascular Centre (CVC), Groningen Kidney Center (GKC), Restoring Organ Function by Means of Regenerative Medicine (REGENERATE), ACS - Amsterdam Cardiovascular Sciences, Cardiology
Jazyk: angličtina
Rok vydání: 2013
Předmět:
CHRONIC KIDNEY-DISEASE
Male
DARBEPOETIN-ALPHA
medicine.medical_treatment
law.invention
Percutaneous coronary intervention
Randomized controlled trial
law
REPERFUSION
Pharmacology (medical)
Myocardial infarction
NEOVASCULARIZATION
Clinical outcome
General Medicine
Middle Aged
DOUBLE-BLIND TRIAL
Recombinant Proteins
surgical procedures
operative
Cardiology
HEART-FAILURE
Female
Cardiology and Cardiovascular Medicine
therapeutics
medicine.drug
medicine.medical_specialty
CLINICAL-TRIAL
SDG 3 - Good Health and Well-being
Internal medicine
Thromboembolism
medicine
Humans
cardiovascular diseases
ANEMIA
Erythropoietin
Aged
Pharmacology
Intention-to-treat analysis
business.industry
Epoetin alfa
RECOMBINANT-HUMAN-ERYTHROPOIETIN
medicine.disease
Epoetin Alfa
Conventional PCI
Hematinics
Myocardial infarction complications
business
Zdroj: Cardiovascular Drugs and Therapy, 27(5). Kluwer Academic Publishers
Cardiovascular Drugs and Therapy, 27(5), 433-439
fokkema, M L, Kleijn, L, van der Meer, P, Belonje, A M S, Achterhof, S K, Hillege, H L, van't Hof, A W J, Jukema, J W, Peels, H O, Henriques, J P, ten Berg, J M, Vos, J, van Gilst, W H, van Veldhuisen, D J & Voors, A A 2013, ' Long term effects of epoetin alfa in patients with ST-elevation myocardial infarction. ', Cardiovascular Drugs and Therapy, vol. 27, no. 5 . https://doi.org/10.1007/s10557-013-6470-0
Cardiovascular Drugs and Therapy, 27(5), 433-439. SPRINGER
Cardiovascular drugs and therapy / sponsored by the International Society of Cardiovascular Pharmacotherapy, 27(5), 433-439. Kluwer Academic Publishers
ISSN: 0920-3206
Popis: Purpose: The HEBE III trial showed that epoetin alfa administration in patients with a first ST-elevation myocardial infarction (STEMI) did not improve left ventricular function at 6 weeks after primary percutaneous coronary intervention (PCI). The long term effects of erythropoiesis- stimulating agents on cardiovascular morbidity and mortality are unknown, therefore we evaluated clinical events at 1 year after PCI. Methods: A total of 529 patients with a first STEMI and successful primary PCI were randomized to standard optimal medical treatment (N = 266) or an additional bolus of 60,000 IU epoetin alfa administered intravenously (N = 263) within 3 h after PCI. Analyses were performed by intention to treat. Results: At 1 year after STEMI, 485 patients had complete follow-up. The rate of the composite end point of all-cause mortality, re-infarction, target vessel revascularization, stroke and/or heart failure was 6.4 % (N = 15) in the epoetin alfa group and 9.6 % (N = 24) in the control group (p = 0.18). Thromboembolic events were present in 1.3 % (N = 3) of patients in the epoetin alfa group and 2.4 % (N = 6) in the control group. There was no evidence of benefit from epoetin alfa administration in subgroups of patients. Conclusions: Administration of a single bolus of epoetin alfa in patients with STEMI does not result in a reduction of cardiovascular events at 1 year after primary PCI. There was a comparable incidence of thromboembolic complications in both treatment groups, suggesting that epoetin alfa administration is safe at long term. © 2013 Springer Science+Business Media New York.
Databáze: OpenAIRE
Externí odkaz: